Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of Moderate Buy from Brokerages

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has given a strong buy […]

Related Keywords

Pascal Deschatelets ,Alec Machiels ,Vanguard Group Inc ,Nasdaq ,News Ratings For Apellis Pharmaceuticals Daily ,Apellis Pharmaceuticals Inc ,Jacobs Levy Equity Management Inc ,Analyst Recommendations For Apellis Pharmaceuticals ,Polar Capital Holdings Plc ,Citigroup ,Jpmorgan Chase Co ,Comerica Bank ,Wells Fargo Company ,Apellis Pharmaceuticals ,Apellis Pharmaceuticals Price Performance ,Get Free Report ,Marketbeat Ratings ,Wells Fargo ,Director Alec Machiels ,Bay Capital Management ,Capital Holdings Plc ,Jacobs Levy Equity Management ,Get Free ,Apellis Pharmaceuticals Daily ,Nasdaq Apls ,Apls ,Medical ,Ratings ,Consensus ,